0001214659-23-017028.txt : 20231228
0001214659-23-017028.hdr.sgml : 20231228
20231228170700
ACCESSION NUMBER: 0001214659-23-017028
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20231201
FILED AS OF DATE: 20231228
DATE AS OF CHANGE: 20231228
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: KAZIMI A J
CENTRAL INDEX KEY: 0001075050
ORGANIZATION NAME:
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-33637
FILM NUMBER: 231523406
MAIL ADDRESS:
STREET 1: 1207 17TH AVENUE SUITE 103
CITY: NASHVILLE
STATE: TN
ZIP: 37212
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CUMBERLAND PHARMACEUTICALS INC
CENTRAL INDEX KEY: 0001087294
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
ORGANIZATION NAME: 03 Life Sciences
IRS NUMBER: 000000000
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE,
STATE: TN
ZIP: 37203
BUSINESS PHONE: 615-255-0068
MAIL ADDRESS:
STREET 1: 2525 WEST END AVENUE
STREET 2: SUITE 950
CITY: NASHVILLE
STATE: TN
ZIP: 37203
4
1
marketforms-63937.xml
PRIMARY DOCUMENT
X0508
4
2023-12-01
0001087294
CUMBERLAND PHARMACEUTICALS INC
CPIX
0001075050
KAZIMI A J
1600 WEST END AVE.
SUITE 1300
NASHVILLE
TN
37203
true
true
true
false
Chairman and CEO
1
Common Stock
2023-12-01
5
L
false
E
72
1.69
A
5720165
D
Common Stock
2023-12-04
5
L
false
E
64
1.72
A
5720229
D
Common Stock
2023-12-05
5
L
false
E
72
1.69
A
5720301
D
Common Stock
2023-12-06
5
L
false
E
72
1.70
A
5720373
D
Common Stock
2023-12-07
5
L
false
E
34
1.65
A
5720407
D
Common Stock
2023-12-08
5
L
false
E
72
1.83
A
5720479
D
Common Stock
2023-12-11
5
L
false
E
82
1.85
A
5720561
D
Common Stock
2023-12-12
5
L
false
E
87
1.77
A
5720648
D
Common Stock
2023-12-13
5
L
false
E
82
1.80
A
5720730
D
Common Stock
2023-12-14
5
L
false
E
82
1.86
A
5720812
D
Common Stock
2023-12-15
5
L
false
E
82
1.89
A
5720894
D
Common Stock
2023-12-18
5
L
false
E
81
1.80
A
5720975
D
Common Stock
2023-12-19
5
L
false
E
81
1.73
A
5721056
D
Common Stock
2023-12-20
5
L
false
E
124
1.76
A
5721180
D
Common Stock
2023-12-21
5
L
false
E
87
1.70
A
5721267
D
The reported purchases occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May16, 2023.
A.J. Kazimi by /s/ John Hamm as attorney-in-fact
2023-12-28